During puberty an Increase In LH secretion, as measured by RIA, Is observed. Other studies have reported an increasing ratio of bioactivity over lmmunoactivily of LH durlng puberty. In order to study the relationship between l k y i t u biological (bLH) and Immunological (ILH) LH secretion durlng normal pubertal development. bLH and ILH was measured in 62 normal children (31 boys. 31 girls) in different stages of puberty Plasma samples were derived at 1 hour intervals durlng 3 hours daytlme and 3 hours nlghnlme. BLH was measured by the Mouse Leydlg Cell Assay (MLCA) and ILH was measured by IRMA. Results: m: mean bLH and mean ILH significantly increased during puberty, with a maximum at G4 (GI: day + night bLH ~0 . 3 U/I and day + nlght ILH <0.3 U/i, G4: day bLH 1.36 U/I sd 0.63, night 3 57 U/I sd 1.43: day ILH 1.14 U/I sd 0.62, nlqht 4.33 U/I sd 1.29; Kruskai-Wallls oneway anova.p<0.01). A correlation is found between bLH and ILH, In all samples studled durlng daytime and nighttime (R=O 85, p<0.01) At daytime, the ratio of the ICWULQ bioacnvi~ and the ~mmunoactivity (611 ratlo) is 1.3 sd 0.2 in stages ~2 .~4 , slgnlficantly higher compared to B/I 0.7 sd 0.2 In G5 (K-W oneway anova.pc0 05)
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During night B/I ratio is < 1 and does not differ In all stages. W. for both MH and ILH a slgnlflcant increase during puberty is seen, with a maximum at M4 (MI: day+night bLH, day + night ILH ~0 . 3 U/I; M4: day bLH 1.87 U/I sd 1.03, night 2.63 U/i sd 1.29; day ILH 2.45 U/I sd 1.73, night 5.03 U/I sd 2.37: K-W oneway ANOVA, p<0.01). BLH significantly correlates with ILH (R=0.87, pc0.01). In contrast to boys, no signlllcant changes I n B/I ratio are detected in girls during puberty. In conclusion: during ncfmal puberty, the changing LH bloactlvlty slgnlficantly correlates with ILH. In glrls the LH 811 ratio does not change. In boys an Increased B/I ratlo is found in stages G2-G4 during the day, which may be due to the low daytlme testosterone levels, associated wlth the day-night rhythm. (MP), lhs pulralile arc. of GI1 secretion (PA) or in h e lolal area of G H recielton nA). In addtlion. lhs frqucncy of MGii < 3 ndml war similar in all erperimmlal groupr (12) flablc).
PATIENTS WITH CONSTITUTIONAL DELAY OF GROWTH

-"--:
Patient~ in lho prepuberml period of life w~l h CDGP erhlb>! a rpon~ancour GH rcnecion h a t is quantitatively similar lo normal chlldrcn in h e same pcrlod of I>h. Hence. we porh~lalc ha! lhc decreasc of grawlh velocily lhal romc paticnu wilh CDGP show is no, due lo a !ianrilory GH dcficiencv.
PROSPECTIVE RANDOMISED STUDY OF THE EFFECTS OF TREATMENT WITH E I T H E R LOW DOSE OXANDROLONE OR TESTOSTERONE OR PLACEBO ON THE P I T U I T A R Y -TESTICULAR A X I S I N BOYS W I T H CDGP.
EC Crowne WHB Wallace, C Moore, WR Robertson, I Morris, SM S h a l e t . C h r i s t i e 2nd Hope Hospitals, RHCH, Medical School, Manchester, U K .
16 boys w i t h CDGP i n e a r l y puberty (mean(S.D)age 14.2(0.7) yeara, bane age l l . l ( O . 9 ) yeara, t e s t i c u l a r volume 4-6 m l s ) were randomly assigned t o treatment for 3 months wlth placebo (group 1 , n i 5 ) . oxandrolone 2 . 5 mg daily (group 2, n=5) o r testosterone 4 weekly 5 0 mg i m i n j e c t i o n (group 3 , n.6). A e s e e s m e n t s were a t 0, 3 , 6 and 1 2 months and consisted of pubertal development, and 1 2 hour overnight hormone p r o f i l e e with 1 5 minute samples. LH w a s a s e a y e d ueing a highly s e n s i t i v e IRMA (Maiaclone, Serono), each p r o f i l e i n one assay. Testosterone w a s measured following ether extraction, and rnhibin by R I A . LH p r o f i l e s were analyeed ;sing a peak detection programme ( P u l s a r ) , Fourier transformation a n d autocorrelation techniques. RESULTS. Mean t e e t i c u l a r volume increased t o 6 . 7 . 7 . 6 a n d 8 . 8 m l s i n ---~ Groups 1 , 2 and 3 respectively a t 1 2 monthe (p=0.05, 0.04 and 0.015). group 3 a l s o showed a s r g n r f~c a n t rncreaee a t 6 montha (p=0.04). There was a progressive increase i n mean LH concentration, area under t h e c u r v e ( A U C ) a n d number of LH peaks i n group 1 o v e r 1 2 monthe, b u t LH p r o f i l e e i n Groups 2 a n d 3 s h o w e d a decrease in t h e s e parameters a t 3 monthe. Mean LH, number of LH peak8 and AUC rncreaaed s i g n i f i c a n t l y between 3 and 6 months i n group 3 (p=0.002, 0.03 and 0.001 respectively). Fourier transformation a n d autocorrelation revealed dominant LH p c r r o d~c i t y i n group 2 a t 1 2 monthe and group 3 a t 6 months b u t not in group 1 a t any time. I n h i b~n levels decreased a t 3 months in group 2 and 3 , a n d testosterone l e v e l s decreased a t 3 m o n t h e i n group 2 b u t both ~n h i b i n and teatasterone l e v e l s gradually increased throughout the 1 2 months in group 1 . CONCLUSION Both oxandrolone and teetoeterone i n low dosage may a f f e c t the p i t u i t a r y -t o n t i c u l a r a x i s b u t t h r s a f f e c t appears traneiont.
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CRANIAL IRRADIATION AND EARLY PUBERTY Bl, O e i l v v -m , PE Claylon, SM Shalet Department of Endocrinology, Christie Hospilal, Manchester, M20 9BX, UK. Low doses of cranial irradiation (1800-2400 cGy) employed in the management of acute lymphoblastic leukaemia may cause early or precocious puberty in girls but not boys. To determine if this sexual dichotomy exists at higher irradiation doses (2500-4700 cGy) the onset of puberty was identified in 46 children (30 male), previously irradiated for a brain tumour not involving the hypothalamic-pituikry axis, and compared with the normal pubertal standards of Tanner. Regression analysis was employed to assess whether tumour diagnosis, sex, age at irradiation. chemotherapy, use of GH before puberty and radiotherapy protocol influenced age at pubertal onset. The onset of puberty occurred at an early age in both sexes (mean 8.51 years in girls and 9.21 years in boys plus 0.29 years for every year of age at irradiation). In the context of GH deficiency which is usually associated with a delay in the onset of puberty this is abnormal. There was a significant linear association between age at irradiation and age at onset of puberty in both sexes. At each age of irradiation the estimated age at the onset of puberty was approximately 0.7 years earlier in girls than boys. A similar trend was seen for bone age, which was abnormally early at the time of pubcrlal onset (mean 7.39 years in girls and 8.66 years in boys plus 0.25 years for every year of age a1 the time of irradiation). Radiation induced early puberty is not restricted to females at the doses of irradiation employed in the treatment of brain tumours. The clinical consequence of early puberty in the management of poor growth associated with radiation induced GM deficiency is to foreshorten the time available for treatment with GH. We investigated the pharmacokinetics and the effects on sexual mawration and growth of HPBCD complexed SL-T in five prepubenal males aged 14-17 years with CDGP. Patients were treated with 2.5 mg SL testosterone TID for 12 weeks. Patients revealed no evidence of side effects and had greater than 95% compliance with the drug regimen. SL-T raised serum testosterone (T) levels from a baseline of 2@10 to a peak of 14Wk120 ng/dl within 20 minutes with a half life of 2515 minutes. Serum estradiol and gonadotropin levels were not acutely affected by SL-T. SL-T kinetics were not significantly changed after 12 weeks of therapy. In three patients followed over 6-18 months after the SL-T course, sexual maturation svage progressed from stage I to stage 11-1'4, testicular volume increased from 2 i l to I l i 4 ml, growth velocity increased from 4 i l to 1112 c d y e a r , and height SDS rode from -2.510.2 to -1.8H.5. Serum testosterone levels increased from 2M10 to 25M100 ngldl, and serum IGF-I levels rose from 15M30 to 300i60 ng/ml. Bone age advanced from I l t l to 13i0.5 years over 1.210.3 years while predicted adult height remained unchanged. Our preliminary data suggest that a 12 week course of SL-T is a safe, effective, and well accepted ueatrnent for the induction of puberty and the concurrent promotion of growth in male adolescents with CDGP. Urine concentrates assessed by RIA provide as sensitive a methodology for gonadotropin measurements as newly available immunofluorometric techniques. The ease of obtaining repeated, short-term (3-6hr), timed urine specimens and allowing the lddney to integrate for pulsatile secretion lends itself to distinguishing patientr with gonadotropin deficiency from those wilh constitutional delay in adolescence. We have compared the rate of gonadotropin rise in males between the ages of 12-18 yrs. in 48 normal boys, 96 patients with constitutional delay, 19 patients with isolated gonadotropin deficiency, and 10 patients with multiple tropic hormone deficiency. A tolal of 511 specimens were analyzed by a longitudinal model that allowed for separate intercepts and linear slopes on log transformed dab for each of the four diagnostic categories. For LH, the linear equation describing the constitutional group was log LH=0.6 + 0.32 x age @<0.0001 for slope of line) but for the isolated hypogonadotropic patients was log LH=4.14 + 0.03 x age @=0.74). Using a Bonferroni correction, the rate of hormone increase was markedly different for the constitutional delayed boys as compared to the hypogonadotropic patients @=0.02). Similar findings existed for FSH. The model utilized provides a guide for determining the appropriate diagnosis for a patient with delayed adolescence who is followed for a year or more with sequential gonadotropin determinations. Inconclvsion a separation of adolescent boys with hypogonadotropism from those who have constitutional delay can be made by S85 following sequential urine gonadotropin determinations over a year or more.
TREATMENT OF ADOLESCENT MALES WlTH CONSTITUTIONAL DELAY OF GROWTH AND PUBERTY (CDGP) WITH SUBLINGUAL TESTOSTERONE (SL-T) COMPLEXED WlTH HYDROXYPROPYL-O-CYCLODEXTRIN (HPBCD
USEFULNESS OF SEQUENTIAL URINE FSH AND LII MEASUREMENTS
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